Kazuoki Kondo, MD
Tanabe Pharma Corporation
20
0
20
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+18 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Takashi Kadowaki, Professor
Tokyo University
Shared therapeutic areas:
Worked with same sponsors:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Takashi Kadowaki, MD
Tokyo University
Shared therapeutic areas:
Worked with same sponsors:
Tadashi Yoshida, MD
Tanabe Pharma Corporation
Shared therapeutic areas:
Worked with same sponsors:
ali ismail, lecturer
Cairo University
Shared therapeutic areas:
Yoshiya Tanaka, MD
University of Occupational and Environmental Health
Shared therapeutic areas:
Worked with same sponsors:
Nobuya Inagaki, MD
Kyoto University
Shared therapeutic areas:
Worked with same sponsors:
Mamoru Watanabe, MD
Tokyo Medical and Dental University
Shared therapeutic areas:
Worked with same sponsors:
Nobuya Inagaki, MD
Kyoto University, Graduate School of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Tsutomu Takeuchi, MD
Keio University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (20)
Showing 20 of 20 trials
Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes
Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients
Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease
Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
All 20 trials loaded